Search

Objectives To determine risks associated with uricosurics in COVID-19 patients. Methods A systematic review and meta-analysis was conducted by systematically searching electronic databases. Key findings The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94–1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65–0.94). Conclusions The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties. [ABSTRACT FROM AUTHOR]